BioCentury
ARTICLE | Clinical News

TAK-375: Phase II data; Phase III

June 16, 2003 7:00 AM UTC

In a randomized, double-blind U.S. trial in 375 healthy adults, both 16 and 64 mg doses of TAK-375 produced significantly shorter mean LPS than placebo (12.2 and 13.4 minutes vs. 22.6 minutes, p<0.001...